Clinical-stage precision medicine company EXACT Therapeutics AS (Euronext Growth Oslo:EXTX) announced on Wednesday that it has been granted a patent in the UK covering its proprietary Acoustic Cluster Therapy (ACT) platform for non-invasive drug delivery to the central nervous system.
UK Patent no. 2104590.1 protects ACT's use in treating brain-related diseases, including glioblastoma, by overcoming the challenges of the blood-brain barrier. This marks the first territory approval for this patent, representing a key milestone in the development of EXACT's central nervous system (CNS) pipeline.
ACT leverages ultrasound technology to enhance targeted delivery of pharmaceuticals, potentially expanding therapeutic access to larger brain areas.
EXACT recently reported promising non-clinical results in glioblastoma, highlighting ACT's potential as a novel approach in neuro-oncology.
The company continues to advance ACT as part of its broader precision medicine strategy in oncology.
Bionpharma and STEERLife's Etravirine tablets approved by US FDA
Rakuten Medical signs manufacturing agreement with LOTTE Biologics
Kestra partners with Biobeat to add cuffless blood pressure monitoring to wearable defibrillator
Curasight reports preliminary data from Phase 1 trial in patients with high-grade gliomas
Abbisko Therapeutics reports US FDA acceptance of pimicotinib NDA
Viking Therapeutics publishes Phase 2 data showing up to 14.7% weight loss with VK2735
Formosa Pharmaceuticals licenses APP13007 ophthalmic therapy to Samil for South Korea
Summit Therapeutics and GSK form collaboration to study ivonescimab combination therapy
Summit Therapeutics submits FDA application for ivonescimab in EGFR-mutated lung cancer
Sanofi's Teizeild approved in EU to delay stage 3 type 1 diabetes
Renalytix expands US clinical footprint with three kidneyintelX.dkd integrations